{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:08Z","timestamp":1792718348109,"version":"4.5.0"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Eosinophilic esophagitis (EoE) is a chronic, progressive, immune-mediated disease of the esophagus. Esophageal dysfunction in solid food dysphagia combined with eosinophil-dominant inflammation (\u2a7e15 eos\/high-power-field (hpf)) serves as diagnostic criteria. Treatment objectives for active EoE include induction and maintenance of clinical-histological remission. Topical budesonide therapy in the form of an orodispersible tablet (BUD-ODT) has shown effectiveness in both scenarios.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To examine the efficacy and safety of BUD-ODT therapy in adults with active EoE in a Real-World-Setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>This retrospective study from two German EoE centers examined the efficacy and safety of BUD-ODT therapy in adults with active EoE between June 2018 and August 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>\n              Patient demographics, clinical characteristics, and EoE history were extracted from medical records. Evaluations included clinical (Straumann Dysphagia Index, range: 0\u20139, remission: \u2a7d3\u2009points), histological (remission: \u2a7d15 eos\/hpf), and endoscopic assessment (endoscopic reference scoring system (EREFS) score, range: 0\u20139, remission: \u2a7d2\u2009points). Three periods were analyzed: Induction phase (induction therapy (IT): 1\u2009mg BID, 6\u201312\u2009weeks;\n              <jats:italic>n<\/jats:italic>\n              \u2009=\u2009201), maintenance phase I (RM1: 0.5\u2009mg BID or 1\u2009mg QD, 14\u201324\u2009weeks;\n              <jats:italic>n<\/jats:italic>\n              \u2009=\u2009109), and maintenance phase II (RM2: same dosage as RM1, 52\u2013104\u2009weeks;\n              <jats:italic>n<\/jats:italic>\n              \u2009=\u200972).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 221 adults with clinical-histologically proven active EoE were included. Clinical-histological remission was achieved in 75.1% (151\/201) of patients after IT, maintained in 73.4% (80\/109) after RM1, and in 76.4% (55\/72) after RM2. The relapse rate was 26.6% (29\/109) after RM1 and 23.6% (17\/72) after RM2. Those patients underwent re-induction therapy for 6\u20138\u2009weeks and were re-evaluated separately (remission: 36.0% after RM1 and 46.2% after RM2). Endoscopic remission was demonstrated in 88.1% (177\/201) after IT. The most prevalent side effect was endoscopically detected combined oral-esophageal candidiasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>BUD-ODT demonstrated high effectiveness in inducing and maintaining remission in a real-world setting. The spectrum of side effects did not reveal any new aspects compared to known clinical data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/17562848251382791","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:45:49Z","timestamp":1759913149000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world-data on efficacy and safety of topical budesonide therapy (orodispersible tablet) in induction and maintenance therapy in adult patients with active eosinophilic esophagitis"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4435-6937","authenticated-orcid":false,"given":"Maja","family":"Weisfeld","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious diseases, University Hospital Magdeburg, Leipziger Str. 44, Magdeburg 39120, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9297-3349","authenticated-orcid":false,"given":"Stephan","family":"Miehlke","sequence":"additional","affiliation":[{"name":"Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Meszaros","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Dr. Falk Pharma GmbH, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Keitel-Anselmino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious diseases, University Hospital Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0166","authenticated-orcid":false,"given":"Ulrike von","family":"Arnim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious diseases, University Hospital Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640616689525"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/a-2060-1142","article-title":"Aktualisierung der S2k-Leitlinie Gastro\u00f6sophageale Refluxkrankheit der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)","volume":"61","author":"Madisch A","year":"2023","unstructured":"Madisch A, Koop H. Aktualisierung der S2k-Leitlinie Gastro\u00f6sophageale Refluxkrankheit der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2023; 61: 797\u2013798.","journal-title":"Z Gastroenterol"},{"key":"e_1_3_4_4_2","volume-title":"Gastroenterol","volume":"155","author":"Dellon ES","year":"2018","unstructured":"Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterol 2018; 155: 1022\u20131033.e10."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.018"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2013.10.027"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0052-5"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.01.019","article-title":"Efficacy of elimination diets in eosinophilic esophagitis: a systematic review and meta-analysis","volume":"21","author":"Mayerhofer C","year":"2023","unstructured":"Mayerhofer C, Kavallar AM, Aldrian D, et al. Efficacy of elimination diets in eosinophilic esophagitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023; 21: 2197\u20132210.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13281"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820927282","article-title":"Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence","volume":"13","author":"Miehlke S","year":"2020","unstructured":"Miehlke S, Lucendo AJ, Straumann A, et al. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. Therap Adv Gastroenterol 2020; 13: 175628482092728.","journal-title":"Therap Adv Gastroenterol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo AJ","year":"2019","unstructured":"Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterol 2019; 157: 74\u201386.e15.","journal-title":"Gastroenterol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"159","author":"Straumann A","year":"2020","unstructured":"Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterol 2020; 159: 1672\u20131685.e5.","journal-title":"Gastroenterol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pds.5507","article-title":"Harmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force","volume":"32","author":"Wang SV","year":"2023","unstructured":"Wang SV, Potteg\u00e5rd A, Crown W, et al. Harmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force. Pharmacoepidemiol Drug Saf 2023; 32: 44\u201355.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.202"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.10.027"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12220"},{"key":"e_1_3_4_17_2","first-page":"60","article-title":"Budesonide orodispersible tablets are able to maintain clinical, histological and endoscopic remission in adult patients with eosinophilic esophagitis: results from the 96-weeks open-label extension phase following the 1-year double-blind EOS-2 trial","author":"Biedermann L.","year":"2022","unstructured":"Biedermann L. Budesonide orodispersible tablets are able to maintain clinical, histological and endoscopic remission in adult patients with eosinophilic esophagitis: results from the 96-weeks open-label extension phase following the 1-year double-blind EOS-2 trial. United European Gastroenterol J 2022; 10: 60\u201361.","journal-title":"United European Gastroenterol J"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.08.038"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86464-z"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001850"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.05.066"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.11.004","article-title":"Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis","volume":"150","author":"Safroneeva E","year":"2016","unstructured":"Safroneeva E, Straumann A, Coslovsky M, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterol 2016; 150: 581\u2013590.e4.","journal-title":"Gastroenterol"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000514"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1855-1974"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.5056\/jnm21143"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251382791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251382791","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251382791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:26:50Z","timestamp":1760275610000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251382791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"alternative-id":["10.1177\/17562848251382791"],"URL":"https:\/\/doi.org\/10.1177\/17562848251382791","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"17562848251382791"}}